You are here

  • Home
  • Archive
  • Volume 11, Issue 3
  • Phase II study of nivolumab and salvage nivolumab/ipilimumab in treatment-naïve patients with advanced non-clear cell renal cell carcinoma (HCRN GU16-260-Cohort B)

Article metrics

Article menu
Clinical/translational cancer immunotherapy
Original research
Phase II study of nivolumab and salvage nivolumab/ipilimumab in treatment-naïve patients with advanced non-clear cell renal cell carcinoma (HCRN GU16-260-Cohort B)

 

Online download statistics by month:

Online download statistics by month: March 2023 to February 2026

AbstractFullPdf
Mar 202329830378
Apr 202321922365
May 202329830521
Jun 202318518727
Jul 202317017029
Aug 202319319336
Sep 202315815933
Oct 202314114245
Nov 202314514630
Dec 202311311421
Jan 2024959553
Feb 202410410442
Mar 202411911970
Apr 202412312861
May 202413813855
Jun 202411812049
Jul 202413613762
Aug 202411811632
Sep 2024757653
Oct 202410211260
Nov 202411111532
Dec 202412512640
Jan 202510510544
Feb 2025707031
Mar 202510810853
Apr 202511011066
May 2025939671
Jun 2025818149
Jul 2025110
Aug 2025110
Feb 2026110
Total385439011308